BTK inhibitors Ibrutinib and ACP-196 were relatively well tolerated in metastatic PDA patients with the combination of chemotherapy or immune checkpoint blockade (NCT02403271, NCT02362048, NCT02562898). Here, BTK is linked to Patent ductus arteriosus.